Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Breaking up the Superbugs’ Party

Published: Friday, August 16, 2013
Last Updated: Friday, August 16, 2013
Bookmark and Share
The fight against antibiotic-resistant superbugs has taken a step forward thanks to a new discovery by scientists.

A BBSRC-funded multi-disciplinary research team at the University's Centre for Biomolecular Sciences has uncovered a new way of inhibiting the toxicity and virulence of the notorious superbug, Pseudomonas aeruginosa.

These bacteria are resistant to many conventional antibiotics. It is almost impossible to eradicate P. aeruginosa from the lungs of people with cystic fibrosis and is therefore a leading cause of death among sufferers. The bug also causes a wide range of infections particularly among hospital patients.

The new discovery concerns the bacterial cells' ability to 'talk' to each other by producing and sensing small chemical signal molecules. This is called 'quorum sensing' (QS) and enables a population of individual bacteria to act socially rather than as individuals. QS allows a population of bacteria to assess their numerical strength and make a decision only when the population is 'quorate'.

The mechanism through which QS signals work is by activating gene expression upon interaction of a QS signal molecule with a receptor protein. In many disease-causing bacteria, QS controls genes which are essential for infection. These genes code for virulence factors such as toxins which cause damage to host tissues and the immune system. Interfering with the QS signalling process blocks bacterial virulence and renders bacteria unable to cause infection. Consequently QS systems are molecular targets for the development of new anti-infective drugs which do not kill bacteria but instead block their ability to cause disease.

In a study published in the journal, PLOS Pathogens, the Nottingham team has described how they solved the 3D structure of a receptor protein called PqsR used by P. aeruginosa to sense alkyl quinolone QS signal molecules so that they could visualize the shape of the QS signal molecule-binding site within the PqsR protein.

Professor of Molecular Microbiology, Paul Williams, said: "We were able to synthesize and screen a library of chemical compounds which could fit within the PqsR binding site and block receptor activation by the QS signal molecules. The active compounds were screened for their ability to inhibit QS and through a process of chemical refinement some novel potent QS inhibitors were discovered which were tested biologically on P.aeruginosa and shown to block virulence gene expression."

Professor of Macromolecular Crystallography, Jonas Emsley, added: "This ground-breaking work establishes a platform for the future evaluation and further development of these new QS inhibitor compounds as potential drugs for the treatment of P. aeruginosa infections."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Drugs Used to Treat Lung Disease Work With the Body Clock
Scientists from The University of Manchester have discovered why medication to treat asthma and pneumonia can become ineffective.
Thursday, August 14, 2014
Prions, vCJD and the Immune System Relay
BBSRC is helping to shed new light on variant Creutzfeldt-Jakob disease.
Friday, December 06, 2013
Researchers Have a Nose for How Probiotics Could Affect Hay Fever
A study has shown that a daily probiotic drink changed how cells lining the nasal passages of hay fever sufferers reacted to a single out-of-season challenge.
Thursday, November 28, 2013
New Technique for Developing Drugs
An international team of researchers have created a new drug for possible use against heart disease, inflammation and other illnesses.
Monday, November 18, 2013
£60,000 Competition to Recognise Innovative Scientists Launched by BBSRC
Innovator of the Year 2014 competition launched by BBSRC to recognise and reward scientist's whose excellent science and innovations are delivering real world impact.
Friday, July 12, 2013
Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Mucus – the First Line of Defence
Researchers reveal the important role of mucus in building a good defence against invaders.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos